Clinical trial
How to Predict Response to Acute Treatment of Migraine With Rimegepant 75 mg: a Biochemical and Neurophysiological Study.
NCT05888766 is registered in ClinicalTrials.gov with University of Roma La Sapienza as lead sponsor.
Search trials, sites, companies and investigators, and follow each one to the others. Individual plan, $249/seat/mo. Card required.
Registry record
As filed in ClinicalTrials.gov.
- Title
- How to Predict Response to Acute Treatment of Migraine With Rimegepant 75 mg: a Biochemical and Neurophysiological Study.
- Lead sponsor
- University of Roma La Sapienza
- Phase
- Observational
- Overall status
- Unknown status
- Start date
- July 1, 2023
- Completion date
- September 30, 2024
- Enrollment
- 20 (estimated)
- Sites
- 1
Conditions
As the registry lists them; a condition with its own page is linked.